Earnings Transcript for EVLO - Q3 Fiscal Year 2021
Disclaimer*:
This transcript is designed to be used alongside the freely available audio recording on this page. Timestamps within the transcript are designed to help you navigate the audio should the corresponding text be unclear. The machine-assisted output provided is partly edited and is designed as a guide.
Operator:
00
Kendra Sweeney:
00
Simba Gill:
02
Mark Plinio:
08
Jonathan Zung:
Thank you, Mark, and good morning, everyone. I will provide an update on our ongoing clinical trials, upcoming readouts, as well as planned studies. 18
Simba Gill:
21
Operator:
22
Chris Howerton:
23
Simba Gill:
24
Chris Howerton:
24
Simba Gill:
24
Duncan McHale:
26
Simba Gill:
27
Jonathan Zung:
27
Chris Howerton:
28
Simba Gill:
28
Mark Plinio:
28
Chris Howerton:
29
Simba Gill :
29
Operator:
29
Matthew Luchini:
29
Simba Gill:
30
Mark Plinio:
31
Jonathan Zung:
31
Matthew Luchini:
32
Duncan McHale :
32
Matthew Luchini:
33
Simba Gill:
33
Operator:
33
Kristen Kluska:
33
Simba Gill:
34
Kristen Kluska:
35
Simba Gill:
35
Mark Plinio:
39
Kristen Kluska:
42
Simba Gill:
42
Operator:
42
Gobind Singh:
42
Simba Gill:
43
Duncan McHale:
Yes. Gobind, thanks for the question. So, I can't really comment on why I'm Amgen chose particular endpoint that they chose. Obviously, they -- as there are [indiscernible] advance. In terms of the body surface are threshold of five percent that they use, that’s sort of -- that's one of the ways in which people can sort of classified psoriasis into mild and moderate disease. It's not necessarily true from patient perspective, it’s really from the physician perspective, we can sort of say that the body surface are is less than five percent in mile, it's greater than five percent in moderate. And I’m assuming that is the reason that they cut that at five percent. And as you saw, we've done something similar and looked at that. 44
Simba Gill:
46
Gobind Singh:
46
Simba Gill:
48
Duncan McHale:
50
Duncan McHale:
52
Gobind Singh:
54
Simba Gill:
54
Operator:
54
Keay Nakae:
54
Simba Gill:
So, we're just generating supply key for the next wave formulations to test in the model that we touched on briefly on the last earnings call. So we just generated supply. And as I said, we should be ready to test different formulations in Q1.
Keay Nakae:
55
Operator:
55
Joseph Thome:
55
Simba Gill:
56
Duncan McHale:
56
Joseph Thome:
57
Simba Gill:
57
Joseph Thome:
57
Operator:
57
Simba Gill:
58
Operator:
59
